PMID- 21082202
OWN - NLM
STAT- MEDLINE
DCOM- 20110810
LR  - 20211020
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 46
IP  - 3
DP  - 2011 Mar
TI  - Effect of rabeprazole treatment on health-related quality of life and symptoms in 
      patients with reflux esophagitis: a prospective multicenter observational study 
      in Japan.
PG  - 297-304
LID - 10.1007/s00535-010-0342-1 [doi]
AB  - BACKGROUND: Despite many reports from Western nations describing endoscopic and 
      symptomatic improvements in patients with reflux esophagitis (RE) using proton 
      pump inhibitors (PPI), PPI effects on the health-related quality of life (HRQOL), 
      particularly for a dose duration of less than 8 weeks, have not been sufficiently 
      clarified in Japanese RE patients. METHODS: RE patients (n = 9,029) in general 
      practice settings took rabeprazole once daily for 8 weeks. HRQOL, using the 
      8-item Short-Form Health Survey (SF-8), and symptoms, using a frequency scale 
      for the symptoms of gastroesophageal reflux disease (GERD), were evaluated at the 
      initiation of therapy (0 W), week 4 (4 W), and week 8 (8 W). Endoscopy was 
      performed at 0 and 8 W where possible. RESULTS: In efficacy analysis (n = 6,839), 
      the mean +/- SD values for the physical component summary of the SF-8 at 0, 4, and 
      8 W were 45.005 +/- 7.534, 48.517 +/- 6.336, and 49.328 +/- 6.207, respectively, while 
      those for the mental component summary were 46.465 +/- 7.743, 49.460 +/- 6.470, and 
      50.388 +/- 6.049, respectively. Significant improvements, compared to 0 W, were 
      observed in eight domains and two summary scores at 4 W (P < 0.001), and further 
      QOL score elevations were seen by 8 W. Regarding symptoms, the mean total 
      frequency scale for the symptoms of GERD (FSSG) scores at 0, 4, and 8 W were 16.4 
      +/- 9.8, 7.8 +/- 7.4, and 6.0 +/- 6.8, respectively. Significant improvements, compared 
      to 0 W, were seen in the total, reflux, and dysmotility scores and in the scores 
      for all 12 items at 4 W (P < 0.001). CONCLUSIONS: The score for the HRQOL of RE 
      patients before rabeprazole therapy was below 50 points (the national mean for 
      the general Japanese population), indicating harmed QOL. Rabeprazole markedly 
      improved the HRQOL at 4 W, with recovery to the national mean by 8 W. Symptoms 
      had also improved significantly at 4 W, with further improvements observed at 8 
      W.
FAU - Hongo, Michio
AU  - Hongo M
AD  - Department of Comprehensive Medicine and Psychosomatic Medicine, Tohoku 
      University Hospital, 1-1 Seiryo-machi, Aoba, Sendai, Miyagi 980-8574, Japan. 
      m-hongo@med.tohoku.ac.jp
FAU - Miwa, Hiroto
AU  - Miwa H
FAU - Kusano, Motoyasu
AU  - Kusano M
CN  - J-FAST Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20101117
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 32828355LL (Rabeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Ulcer Agents/adverse effects/*therapeutic use
MH  - Esophagitis, Peptic/*drug therapy
MH  - Esophagoscopy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Quality of Life/psychology
MH  - Rabeprazole
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2010/11/18 06:00
MHDA- 2011/08/11 06:00
CRDT- 2010/11/18 06:00
PHST- 2010/07/26 00:00 [received]
PHST- 2010/10/19 00:00 [accepted]
PHST- 2010/11/18 06:00 [entrez]
PHST- 2010/11/18 06:00 [pubmed]
PHST- 2011/08/11 06:00 [medline]
AID - 10.1007/s00535-010-0342-1 [doi]
PST - ppublish
SO  - J Gastroenterol. 2011 Mar;46(3):297-304. doi: 10.1007/s00535-010-0342-1. Epub 
      2010 Nov 17.